Citizens JMP lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $3 from $4 and keeps an Outperform rating on the shares. With important data updates coming in Q4, a partnership with Jazz Pharma (JAZZ), and a cash position of $77.6M, Werewolf represents an interesting investment opportunity, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Promising Advancements in Werewolf Therapeutics’ Drug Pipeline Support Buy Rating
- Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Werewolf Therapeutics Reports Q2 2025 Financial Results
- Werewolf Therapeutics sees cash runway into 4Q26
- Werewolf Therapeutics reports Q2 EPS (40c), consensus (37c)